Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe HuangLZLiqun ZouHZHong Yu Zhang

Discussion

Loading...

Member takes

Overview

Clinical analysis reveals that circulating tumor DNA patterns indicate prognosis in early-stage NKTCL, suggesting real-time monitoring benefits.

Key Points

  • This research focuses on the prognostic value of dynamic monitoring of circulating tumor DNA in early-stage natural killer/T-cell lymphoma patients.
  • Analyzed clinical data of 1,825 NKTCL patients from the CSWOG between 2014-2022.
  • Included patients receiving asparaginase-based induction chemotherapy and radiation therapy, monitoring cfEBV-DNA levels.
  • Used Kaplan-Meier and log-rank tests to assess survival outcomes and Cox regression to identify prognostic factors.
  • Performed unsupervised clustering analysis to classify cfEBV-DNA response patterns.
  • 68.6% of patients were cfEBV-DNA positive before treatment; clearance improved during chemotherapy.
  • Achieving cfEBV-DNA negative during treatment phases was linked to significantly better progression-free survival and overall survival.
  • Identified four distinct cfEBV-DNA response phenotypes with varying 5-year survival rates, indicating marked differences in prognosis.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e44bhttps://doi.org/10.1182/blood-2025-1745
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma2026
  2. 2Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy2024 · 20 citations
  3. 3Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  4. 4Abstract 5258: Monitoring of molecular response during immunotherapy by circulating tumor DNA in non-small cell lung cancer2026
  5. 5Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study2024 · 82 citations